117948 20220908120600.0 doi 10.1016/j.ijcha.2021.100851 sideral 127043 ART-2021-127043 eng Biccler, J. Public health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK – Results from micro-simulation model 2021 Access copy available to the general public Unrestricted Background: Low-dose aspirin therapy reduces the risk of cardiovascular disease and may have a positive effect on the prevention of colorectal cancer. We evaluated the population-level expected effect of regular low-dose aspirin use on cardiovascular disease (CVD), colorectal cancer (CRC), gastrointestinal bleeding, symptomatic peptic ulcers, and intracranial hemorrhage, using a microsimulation study design. Methods: We used individual-level state transition modeling to assess the impact of aspirin in populations aged 50–59 or 60–69 years old indicated for low-dose aspirin usage for primary or secondary CVD prevention. Model parameters were based on data from governmental agencies from the UK or recent publications. Results: In the 50–59 years cohort, a decrease in incidence rates (IRs per 100 000 person years) of non-fatal CVD (-203 and -794) and fatal CVD (-97 and-381) was reported in the primary and secondary CVD prevention setting, respectively. The IR reduction of CRC (-96 and -93) was similar for primary and secondary CVD prevention. The IR increase of non-fatal (116 and 119) and fatal safety events (6 and 6) was similar for primary and secondary CVD prevention. Similar results were obtained for the 60–69 years cohort. Conclusions: The decrease in fatal CVD and CRC events was larger than the increase in fatal safety events and this difference was more pronounced when low-dose aspirin was used for secondary compared to primary CVD prevention. These results provide a comprehensive image of the expected effect of regular low-dose aspirin therapy in a UK population indicated to use aspirin for CVD prevention. © 2021 info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 0.803 2021 Cardiology and Cardiovascular Medicine 2021 Q2 3.3 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Bollaerts, K. Vora, P. Sole, E. García Rodriguez, L.A. Lanas, A. Universidad de Zaragoza (orcid)0000-0001-5932-2889 Langley, R.E. Soriano Gabarró, M. 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 36 (2021), 100851 [8 pp] IJC Heart and Vasculature 2352-9067 317385 http://zaguan.unizar.es/record/117948/files/texto_completo.pdf Versión publicada 2498590 http://zaguan.unizar.es/record/117948/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:117948 articulos driver 2022-09-08-11:57:48 ARTICLE